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Congenital Zika virus infection is associated with severe 
brain anomalies and impaired function. To determine out-
comes, we followed 2 affected children for ≈30 months. For 
1 who was symptomatic at birth, transient hepatitis devel-
oped. However, neurodevelopment for both children was 
age appropriate.
Zika virus, a flavivirus, is a teratogenic and neurotropic infectious pathogen (1). Zika virus infection during 
pregnancy causes congenital microcephaly and severe brain 
anomalies (2). In the newly recognized congenital Zika 
syndrome, infection is also associated with partially col-
lapsed skull, retinal damage, congenital contractures, 
early-onset hypertonia, and signs of extrapyramidal in-
volvement; irrespective of a clear pathomechanism, infec-
tion is also associated with intrauterine growth restriction 
and low birth weight (1). Developmental outcomes for 
children born with congenital Zika virus infection have 
been reported for infants with severe brain anomalies as 
consequences of early prenatal exposure (3,4) and include 
postnatal slowing of head circumference growth and im-
paired function. 
After the first large-scale Zika outbreak in French 
Polynesia, October 2013–April 2014 (5), 2 cases of peri-
partum Zika virus infection in full-term neonates were re-
ported (6). We report the follow-up and developmental out-
comes through ≈30 months of age for these 2 children. We 
evaluated cognition by using the Child Development As-
sessment Scale (CDAS), a screening test suitable for chil-
dren 0–5 years of age (online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/23/8/17-0198-Techapp1.pdf).
Case-patient 1 was born at 38 weeks’ gestation; his 
weight, size, and neurologic status were within reference 
ranges for gestational age. His mother manifested a rash, 
suggestive of Zika virus infection, on day 2 after delivery. 
Reverse transcription PCRs for Zika virus were positive in 
blood and saliva from the mother (day 2) and neonate (day 
3) and in breast milk on day 2. The neonate was breast-
fed for 2 months. He remained asymptomatic, and his 
neurologic development followed a typical course. At 32 
months of age, CDAS scores indicated a need to monitor 
motor development but overall did not indicate neurocog-
nitive problems.
Case-patient 2 was also born at 38 weeks’ gestation but 
was small for gestational age (weight 1,925 g; height 42 
cm; head circumference 32 cm). Signs of Zika virus infec-
tion (rash) appeared in the mother on day 3 and in the neo-
nate on day 4. Reverse transcription PCRs for Zika virus of 
blood and urine were positive for the mother (day 1) and 
the neonate (days 4 and 7) and in breast milk on day 8. On 
day 2, laboratory testing of blood from the neonate indicat-
ed thrombocytopenia (65.0 × 109 thrombocytes/L), leuko-
penia (4.6 × 109 cells/L), cytolysis, and cholestasis (Table); 
the cholestasis resolved 4 months later. Ultrasonograms of 
the liver were unremarkable, and albumin levels and hemo-
stasis remained within reference ranges. Breastfeeding was 
maintained for 6 months. At 30 months of age, the child’s 
growth remained within –2 SD for weight (10,725 g) and 
head circumference (47 cm) and –1.5 SD for height (86 
cm). CDAS scores indicated no developmental neurocog-
nitive problems.
Follow-up of these 2 case-patients showed that peripar-
tum Zika virus infection, the exposure situation of mother-
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to-child transmission of Zika virus during gestation (when 
the mother is viremic during childbirth), was associated 
with neither marked illness at birth nor neurodevelopmental 
deficits by 30 months of age. However, assessment of late-
onset cognitive or sensory deficits requires longer follow-up. 
Transmission is assumed unlikely to occur through breast-
feeding; Zika virus isolated from milk is not replicative (6). 
For the 2 case-patients reported here, transmission by con-
tact with the vaginal secretions seems unlikely; viral shed-
ding in these secretions is scarce and weak (7).
Prolonged subclinical hepatitis in case-patient 2, such 
as that observed with congenital cytomegalovirus infec-
tion, resolved after 4 months. To the best of our knowl-
edge, liver pathogenesis in living neonates with Zika vi-
rus infection has not been reported but is common with 
other arboviral (e.g., dengue virus) infections. This milder 
pattern of peripartum Zika virus infection differs from the 
usually severe neonatal dengue virus infection (severe 
thrombocytopenia) and peripartum chikungunya virus in-
fection (postnatal encephalopathy).
Our findings, along with findings of mild brain lesions 
(e.g., subependymal cysts and lenticulo-striate vasculitis) 
after late intrauterine exposure to Zika virus (8), need to be 
replicated on larger populations before it can be suggested 
that placental and blood–brain barriers may be effective 
late in gestation, after fetal maturation. Studies on placen-
tal barrier function have produced discordant results (9,10). 
The primary human trophoblast cells of full-term placentae 
have been shown to be refractory to historic strains of Zika 
virus from Uganda (MR766) and Cambodia (FSS13025). 
However, a contemporary strain of Zika virus from Puer-
to Rico (PRVABC59) was able to infect human placental 
macrophages and mature primary human trophoblast cells 
(9). In addition, primary human trophoblast cells in a non–
Zika virus–endemic population were permissive to a strain 
of Zika virus from Colombia (FLR) (10).
Taken together, uncertainty about the mode of trans-
mission and discrepancies in epidemiologic study findings 
make it imperative to aggregate data to enable compari-
sons of the risk for transmission as a function of exposure 
during gestation. More accurate risk estimates should soon 
be possible thanks to efforts (meta-analyses of individual 
participant data of existing cohorts) of the international 
community, which should enable harmonized follow-up 
and evaluation of developmental outcomes for children ex-
posed to Zika virus.
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Table. Follow-up of liver function test results associated with perinatal Zika virus infection in case-patient 2, French Polynesia, 2014* 
Date (postnatal day) AST, U/L† ALT, U/L‡ GGT, U/L§ Bilirubin, total/conjugate, mg/L¶ 
Feb 4 (2) 84 11 201 158 
Feb 6 (4) 38 12 297 145 
Feb 10 (8) 52 18 457 128/21 
Apr 8 (57) 348 150 281 66/54 
Apr 16 (65) 239 139 312 50/42 
Apr 30 (79) 117 86 239 10 
May 13 (92) 119 104 164 8 
Jun 17 (120) 57 51 40 2 
Oct 25 (250) 38 47 27 2 
*Boldface indicates values out of reference range. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.  
†Reference range 15–40 U/L. 
‡Reference range 10–40 U/L. 
§Reference range 2–34 U/L. 
¶Reference range <14/<3 mg/L. 
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California serogroup (CSG) viruses, such as Jamestown 
Canyon and snowshoe hare viruses, are mosquitoborne 
pathogens that cause febrile illness and neurologic disease. 
Human exposures have been described across Canada, 
but infections are likely underdiagnosed. We describe a 
case of neuroinvasive illness in a New Brunswick, Canada, 
patient infected with a CSG virus.
California serogroup (CSG) viruses (family Bunyaviri-dae, genus Orthobunyavirus) (1) include the mosquito-
borne pathogens Jamestown Canyon virus (JCV), snowshoe 
hare virus (SSHV), and La Crosse virus. Competent vectors 
include non-Culex mosquitoes (e.g., Aedes, Culiseta, and 
Anopheles species), all of which circulate in New Brunswick, 
Canada (2,3). The major reservoir and vertebrate amplifier 
of JCV is believed to be the white-tailed deer (4). Squir-
rels, chipmunks, and hares serve as vertebrate reservoirs for 
SSHV (5). CSG virus infection is generally asymptomatic; 
however, after an incubation period of 3–7 days, a febrile ill-
ness may develop, and central nervous system involvement 
may lead to encephalitis or meningoencephalitis (6). No tar-
geted therapies exist; treatment is supportive.
We describe a previously independent 73-year-old man, 
living on Grand Manan Island, off the Fundy Coast of south-
ern New Brunswick, with a febrile illness that began July 23, 
2015. The man was hospitalized, and the next day he exhibited 
abnormal behaviors (purposeless movements and incoherent 
speech) and became increasingly confused. The confusion 
and fever continued to worsen, and headache and neck pain 
developed. On July 28, he was treated with ceftriaxone and 
transferred to a tertiary-care hospital (Saint John Regional 
Hospital, Saint John, New Brunswick), where ampicillin and 
acyclovir were administered. Cerebral spinal fluid values were 
as follows: leukocyte count, 1 × 106 cells/L (reference range 
0–5 × 106 cells/L); glucose, 3.5 mmol/L (reference range 
2.2–3.9 mmol/L); and protein concentration, 0.58 g/L (refer-
ence range 0.15–0.45 g/L). On July 30, an infectious diseases 
specialist diagnosed the patient with viral encephalitis, most 
likely secondary to herpes simplex virus infection; ceftriaxone 
and ampicillin were discontinued. At a neurology consultation 
on July 31, the patient was still febrile and confused; brain 
magnetic resonance imaging revealed no acute pathology.
On August 4, additional information revealed that 
the patient went on frequent excursions into the woods 
of Grand Manan Island and had exposures to feral cats. 
Doxycycline was initiated, and serologic tests were con-
ducted for Bartonella, Borrelia, Coxiella, and Anaplasma 
species and for Powassan virus, JCV, and SSHV; tests 
were also conducted to rule out paraneoplastic process 
and autoimmune causes. By August 12, the patient was 
afebrile but remained confused. On August 18, PCR was 
negative for herpes simplex virus in CSF, and an electro-
encephalograph revealed no periodic lateralizing epilep-
tiform discharges; acyclovir was discontinued. Initial se-
rologic test results were negative, and the patient showed 
no autoimmune or paraneoplastic markers. During a geri-
atric assessment, the patient showed persistent delirium, 
scoring 13/30 on a mini–mental state examination.
On August 21, we received the patient’s initial CSG 
serology results and collected follow-up serum samples 
for standard serologic testing by IgM capture ELISA and 
plaque-reduction neutralization testing (PRNT) (7,8). The 
acute-phase serum sample was IgM-negative but positive 
for CSG virus–specific neutralizing antibodies by PRNT 
(Table). Serial convalescent-phase serum specimens dem-
onstrated IgM seroconversion several weeks after symptom 
onset and a >4-fold rise in PRNT titers for JCV and SSHV, 
indicating a diagnostic rise. Because serum neutralization 
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